Showing results (511-520 of 536) with videos related to
Sort By:
Pageof 54
Carcinogenesis|July 2, 2014
Identification of a melanoma susceptibility locus and somatic mutation in TET2Fengju Song, Christopher I Amos, Jeffrey E Lee, et al.The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal AdenocarcinomaEugene J Koay, Yeonju Lee, Vittorio Cristini, et al.Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Pigment Cell & Melanoma Research|July 25, 2022
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL studyLi Luo, Ronglai Shen, Arshi Arora, et al.The Lancet. Oncology|February 17, 2018
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisJennifer L McQuade, Carrie R Daniel, Kenneth R Hess, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical OutcomeMarie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.Pageof 54